Artwork

コンテンツは Labiotech によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Labiotech またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!

Reformulating psychedelics for neurodegenerative diseases

41:37
 
シェア
 

Manage episode 406540828 series 3361449
コンテンツは Labiotech によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Labiotech またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal

There is a clear demand for novel, neurological treatments. While it’s widely known psychedelics hold enormous therapeutic potential, there are a host of challenges, including dosing and potential side effects for the patient.

Our guest this week is Dr Sam Clark, who founded Terran Biosciences to develop a safe, effective portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.

00:52-04:09: About Terran Biosciences
04:09-06:03: What are the challenges of using psychedelics?
06:03-07:32: Is there still a stigma attached to use of psychedelics?
07:32-11:45: How do psychedelics work on the brain?
11:45-13:44: Why are psychedelics a good treatment?
13:44-16:51: What is Idazoxan XR?
16:51-18:01: How do you make changes to drugs?
18:01-21:19: How did you develop your business model?
21:19-22:40: What are Eplivanserin and Volinanserin?
22:40-24:49: How useful are repurposed drugs?
24:49-29:06: Keeping drugs affordable
29:06-30:31: Dealing with patents
30:31-32:41: What are empathogens?
32:41-33:12: Where is the company at with clinical trials?
33:12-35:45: What is NM-101?
35:45-37:47: How does Terran differ from other companies?
37:47-39:54: Are you looking to cure conditions?
39:54-40:48: Schizophrenia
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

1. Reformulating psychedelics for neurodegenerative diseases (00:00:00)

2. About Terran Biosciences (00:00:52)

3. What are the challenges of using psychedelics? (00:04:09)

4. Is there still a stigma attached to use of psychedelics?
 (00:06:03)

5. How do psychedelics work on the brain?
 (00:07:32)

6. Why are psychedelics a good treatment?
 (00:11:45)

7. What is Idazoxan XR?
 (00:13:44)

8. How do you make changes to drugs?
 (00:16:51)

9. How did you develop your business model?
 (00:18:01)

10. What are Eplivanserin and Volinanserin?
 (00:21:19)

11. How useful are repurposed drugs?
 (00:22:40)

12. Keeping drugs affordable
 (00:24:49)

13. Dealing with patents
 (00:29:06)

14. What are empathogens?
 (00:30:31)

15. Where is the company at with clinical trials?
 (00:32:41)

16. What is NM-101?
 (00:33:12)

17. How does Terran differ from other companies?
 (00:35:45)

18. Are you looking to cure conditions?
 (00:37:47)

19. Schizophrenia (00:39:54)

103 つのエピソード

Artwork
iconシェア
 
Manage episode 406540828 series 3361449
コンテンツは Labiotech によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Labiotech またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal

There is a clear demand for novel, neurological treatments. While it’s widely known psychedelics hold enormous therapeutic potential, there are a host of challenges, including dosing and potential side effects for the patient.

Our guest this week is Dr Sam Clark, who founded Terran Biosciences to develop a safe, effective portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.

00:52-04:09: About Terran Biosciences
04:09-06:03: What are the challenges of using psychedelics?
06:03-07:32: Is there still a stigma attached to use of psychedelics?
07:32-11:45: How do psychedelics work on the brain?
11:45-13:44: Why are psychedelics a good treatment?
13:44-16:51: What is Idazoxan XR?
16:51-18:01: How do you make changes to drugs?
18:01-21:19: How did you develop your business model?
21:19-22:40: What are Eplivanserin and Volinanserin?
22:40-24:49: How useful are repurposed drugs?
24:49-29:06: Keeping drugs affordable
29:06-30:31: Dealing with patents
30:31-32:41: What are empathogens?
32:41-33:12: Where is the company at with clinical trials?
33:12-35:45: What is NM-101?
35:45-37:47: How does Terran differ from other companies?
37:47-39:54: Are you looking to cure conditions?
39:54-40:48: Schizophrenia
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

1. Reformulating psychedelics for neurodegenerative diseases (00:00:00)

2. About Terran Biosciences (00:00:52)

3. What are the challenges of using psychedelics? (00:04:09)

4. Is there still a stigma attached to use of psychedelics?
 (00:06:03)

5. How do psychedelics work on the brain?
 (00:07:32)

6. Why are psychedelics a good treatment?
 (00:11:45)

7. What is Idazoxan XR?
 (00:13:44)

8. How do you make changes to drugs?
 (00:16:51)

9. How did you develop your business model?
 (00:18:01)

10. What are Eplivanserin and Volinanserin?
 (00:21:19)

11. How useful are repurposed drugs?
 (00:22:40)

12. Keeping drugs affordable
 (00:24:49)

13. Dealing with patents
 (00:29:06)

14. What are empathogens?
 (00:30:31)

15. Where is the company at with clinical trials?
 (00:32:41)

16. What is NM-101?
 (00:33:12)

17. How does Terran differ from other companies?
 (00:35:45)

18. Are you looking to cure conditions?
 (00:37:47)

19. Schizophrenia (00:39:54)

103 つのエピソード

Усі епізоди

×
 
Loading …

プレーヤーFMへようこそ!

Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。

 

クイックリファレンスガイド